期刊文献+

补体C4b及甲状腺素转运蛋白在增生性玻璃体视网膜病变中的表达变化及意义 被引量:7

Differential expression and significance of complement C4b and transthyretin in proliferative vitreoretinopathy
原文传递
导出
摘要 目的探讨补体C4b及甲状腺素转运蛋白(YrR)在增生性玻璃体视网膜病变(PVR)中的表达变化及意义。方法对照实验研究。提取5例PVR患者玻璃体标本,以10例眼球捐献者的玻璃体标本作为正常对照组,进行双向电泳分析。应用Imagemaster软件分析凝胶图谱获得的差异性蛋白质点,再经质谱分析技术鉴定出差异性蛋白质。兔眼玻璃体腔内注射视网膜色素上皮细胞,制造兔PVR模型,采用酶联免疫吸附测定(ELISA)法检测玻璃体中差异性蛋白质的浓度,以进一步验证PVR患者的蛋白质组学结果。PVR患者组与正常对照组玻璃体中差异性蛋白质浓度比较采用配对样本t检验。结果双向电泳凝胶图谱显示PVR患者组与正常对照组玻璃体中有79个差异表达蛋白质点,对其中9个表达上调的差异性蛋白质点进行质谱鉴定,分别为补体CAb、TTR及7个血清蛋白。经ELISA法检测,正常对照组玻璃体中补体C4b和rrrR浓度分别为(20.18±1.97)mg/L和(88.58±8.84)mg/L,PVR患者组玻璃体中补体和1TrR浓度分别为(38.1±5.79)mg/L和(112.57±6.89)mg/L;PVR患者组玻璃体中的补体CAb和TTR浓度明显高于正常对照组,差异有统计学意义(CAb:t=11.54,TTR:t=9.24;P〈0.05)。结论PVR患者组与正常对照组玻璃体中补体CAb和1TTR表达存在差异。补体C4b和TTR的表达上调可能与PVR的发病机制有关。(中华胺科杂志,2011.47:726.731) Objective To investigate the differential expression of complement C4b and transthyretin in proliferative vitreorefinopathy (PVR). Methods It was a controlled experimental study. Human vitreous samples of 5 patients with PVR were analyzed by using two-dimensional gel electrophoresis and mass spectrometry, and the results were compared with those from normal control vitreous obtained from donor eyes. An in vivo model of PVR was created by intravitreous injection of cultured rabbit retinal pigment epithelial (RPE) cells. The vitreous of PVR models were analyzed by enzyme linked immunosorbent assay (ELISA) to confirm the proteomic results from the PVR patients. Results Seventy nine various proteins were expressed differently between PVR and normal vitreous, among which nine up-regulated proteins including complement C4b, transthyretin (TTR), and 7 albumins were identified by mass spectrometry. The up-regulation of complement CAb and TTR in PVR patients was also confirmed by ELISA. The concentration of complement C4b and TTR in normal vitreous were ( 20. 18 ± 1.97 ) mg/L and ( 88.58 ± 8.84 ) mg/L respectively, in PVR patients were ( 38.1 ± 5.79 ) mg/L and ( 112.57 ± 6. 89 ) mg/L repectively, difference significantly between these two groups ( CAb: t = 11. 54, TFR: t = 9. 24; P 〈 0. 05 ). Conclusions Differences of complement CAb and TFR expression were observed between PVR and normal vitreous. These results have lead to the assumption that there is a connection between elevated concentrations of both complement C4b and TTR and the pathogenesis of PVR and further studies on the functions of these proteins are required. (Chin J Opthalmol , 2011,47:726-731 )
出处 《中华眼科杂志》 CAS CSCD 北大核心 2011年第8期726-731,共6页 Chinese Journal of Ophthalmology
基金 浙江省自然科学基金,国家眼科学重点实验室开放课题基金
关键词 玻璃体视网膜病 增生性 补体C4b 甲状腺素转运蛋白 蛋白质组学 电泳 凝胶 双向 质谱分析法 Vitreoretinopathy,proliferative Complement CAb Prealbumin Transthyretin Electrophoresis,gel,two-dimensional Mass spectrometry
  • 相关文献

参考文献28

  • 1Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol, 1997, 115:237-241.
  • 2Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology, 2001, 108 : 1179-1183.
  • 3朱忠桥,王丽丽,刘蓓,王勇.氟尿嘧啶联合低分子肝素预防增殖性玻璃体视网膜病变的临床观察[J].第四军医大学学报,2006,27(15):1421-1424. 被引量:1
  • 4Harry JL, Wilkins MR, Herbert BR, et al. Proteomics : capacity versus utility. Electrophoresis, 2000, 21 : 1071-1081.
  • 5Ouchi M, West K, Crabb JW, et al. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res, 2005, 81:176-182.
  • 6Kim T, Kim S J, Kim K, et al. Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics, 2007, 7:4203-4215.
  • 7Garcia-Ramirez M, Canals F, Hernandez C, et al. Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia, 2007, 50 : 1294-1303.
  • 8Gao BB, Chen X, Timothy N, et al. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabeticretinopathy. J Proteome Res, 2008, 7:2516-2525.
  • 9Yu J, Liu F, Cui SJ, et al. Vitreous proteomie analysis of proliferative vitreoretinopathy. Proteomies, 2008, 8:3667-3678.
  • 10Agrawal RN, He S, Spee C, et al. In vivo models of proliferative vitreoretinopathy. Nat Protoc, 2007, 2:67-77.

二级参考文献7

  • 1The Retina Society Terminology Committee.The classification of retina detachment with proliferative vitreoretinopathy[J].Ophthalmology,1983,90(2):121-125.
  • 2Blumenkranz MS,Hartzer MK,Hajek AS.Selection of therapeutic agents for intraocular proliferative disease.II.Differing antiproliferative activity of the fluoropyrimidines[J].Arch Ophthalmol,1987,105(3):396-399.
  • 3Verstraeten TC,Buzney SM,Macdonald SG,et al.Retinal pigment epithelium wound closure in vitro.Pharmacologic inhibition[J].Invest Ophthalmol Vis Sci,1990,31(3):481-488.
  • 4Borhani H,Peyman GA,Rahimy MH,et al.Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU[J].Int Ophthalmol,1995,19(1):43-49.
  • 5Iverson DA,Katsura H,Hartzer MK,et al.Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy[J].Arch Ophthalmol,1991,109(3):405-409.
  • 6Asaria RH,Kon CH,Bunce C,et al.Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy.Results from a randomized,double-blind,controlled clinical trial[J].Ophthalmology,2001,108(7):1179-1183.
  • 7惠延年.增生性玻璃体视网膜病变:带入21世纪的课题[J].中华眼底病杂志,1999,15(2):67-68. 被引量:34

同被引文献29

引证文献7

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部